Chemically Modified Bacteriophage as a Streamlined Approach to Noninvasive Breast Cancer Imaging
Abstract
I have been able to convert cell surface marker-specific phage identified from library screens into imaging agents that can target and differentiate breast cancer cell types. This is accomplished by using efficient synthetic protocols to conjugate small molecules to phage coat proteins. In the current work, I have examined the use of phage targeting HER2, EGFR, HER3, CD44, and CD73 as immunofluorescence agents in order to visualize these cell surface receptors in cell button models of cancer tissues. Furthermore, I have initiated work whereby the targeting moieties (single chain antibody fragments, or scFv s) displayed by the filamentous phage are displayed on significantly smaller phage types (nanophage), which can be modified similarly and may possess improved biodistribution characteristics compared with the full length fd. I have also initiated the study of chemically modified icosahedral bacteriophage MS2 in order to target specific breast cancer-associated cell surface receptors in cell culture and mouse models of cancer. The work described in this final report ended on July 30, 2013, because I accepted an independent academic position in the chemistry department at the University of Massachusetts, Amherst.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2013
- Accession Number
- ADA596735
Entities
People
- Michelle E. Farkas
Organizations
- University of California, Berkeley